What to expect in the Galera Therapeutics, Inc. interview process

Based on publicly available sources, Galera Therapeutics, Inc. is a public, clinical-stage biopharmaceutical company headquartered in Malvern, Pennsylvania, with an additional office in Creve Coeur. Founded in 2009 and public since 2019, the company focuses on developing novel therapeutics to transform radiotherapy in cancer, including superoxide dismutase (SOD) mimetics like avasopasem and rucosopasem, as well as nitric oxide synthase (NOS) inhibitors like tilarginine.

Data regarding internal workplace culture, day-to-day management style, return-to-office policies, and specific hiring or interview processes are extremely limited in public records. However, organizational metrics reflect a heavily downsized enterprise undergoing significant structural shifts. Employee headcounts have dropped dramatically over recent years—falling from around 30 to 38 employees between 2018 and 2022, down to just 3 to 7 employees in recent years (2023–2025). Financially, the micro-cap company reports minimal annual revenue ($0 to under $1M) and a market cap hovering around $7.4M to $14M, backed by a total historical funding of roughly $204.2M from investors such as New Enterprise Associates and Novartis Venture Fund.

Recent corporate activity includes an all-stock reverse merger announcement in April 2026 with Obsidian Therapeutics to advance cell therapy, alongside a shareholder M&A class action investigation. ESG transparency metrics rated the company low overall (5.1 out of 10), with higher environmental transparency (8.0) contrasting with lower social (3.2) and governance (4.0) scores. Job seekers evaluating Galera should anticipate a hyper-lean, shifting clinical-stage biotech environment shaped by recent corporate restructuring.